FABP1 was reported to correlate with non-alcoholic fatty liver disease [36], and CYP2A13 was found to be involved in the development and progression of lung adenocarcinoma [37]; however, neither of them was previously associated with NSLN metastasis. Here, CYP2A13 is linked to metabolic dysfunction-associated steatotic liver disease.